# Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers

> **NCT05245838** · PHASE1 · COMPLETED · sponsor: **Dynavax Technologies Corporation** · enrollment: 150 (actual)

## Conditions studied

- Shingles
- Herpes Zoster
- Vaccine-Preventable Diseases

## Interventions

- **BIOLOGICAL:** Z-1018
- **BIOLOGICAL:** Z-1018
- **BIOLOGICAL:** Z-1018
- **BIOLOGICAL:** Z-1018
- **BIOLOGICAL:** Shingrix

## Key facts

- **NCT ID:** NCT05245838
- **Lead sponsor:** Dynavax Technologies Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-10
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-10-20
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2022-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245838, "Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-08-19 from https://api.ai-analytics.org/clinical/NCT05245838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*